326 related articles for article (PubMed ID: 10681367)
1. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
Houston JB; Kenworthy KE
Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance.
Griffin SJ; Houston JB
Drug Metab Dispos; 2004 May; 32(5):552-8. PubMed ID: 15100178
[TBL] [Abstract][Full Text] [Related]
3. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
Witherow LE; Houston JB
J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
[TBL] [Abstract][Full Text] [Related]
4. Atypical cytochrome p450 kinetics: implications for drug discovery.
Tracy TS
Drugs R D; 2006; 7(6):349-63. PubMed ID: 17073518
[TBL] [Abstract][Full Text] [Related]
5. Autoactivation and activation of the cytochrome P450s.
Ekins S; Ring BJ; Binkley SN; Hall SD; Wrighton SA
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):642-51. PubMed ID: 9877001
[TBL] [Abstract][Full Text] [Related]
6. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
Lin Y; Lu P; Tang C; Mei Q; Sandig G; Rodrigues AD; Rushmore TH; Shou M
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):368-74. PubMed ID: 11259318
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
[TBL] [Abstract][Full Text] [Related]
8. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.
Naritomi Y; Terashita S; Kimura S; Suzuki A; Kagayama A; Sugiyama Y
Drug Metab Dispos; 2001 Oct; 29(10):1316-24. PubMed ID: 11560875
[TBL] [Abstract][Full Text] [Related]
9. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations.
Jones HM; Houston JB
Drug Metab Dispos; 2004 Sep; 32(9):973-82. PubMed ID: 15319339
[TBL] [Abstract][Full Text] [Related]
10. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data.
Kalvass JC; Tess DA; Giragossian C; Linhares MC; Maurer TS
Drug Metab Dispos; 2001 Oct; 29(10):1332-6. PubMed ID: 11560877
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human pharmacokinetics--gut-wall metabolism.
Fagerholm U
J Pharm Pharmacol; 2007 Oct; 59(10):1335-43. PubMed ID: 17910807
[TBL] [Abstract][Full Text] [Related]
12. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
13. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems.
Baranczewski P; Edlund PO; Postlind H
J Pharm Biomed Anal; 2006 Mar; 40(5):1121-30. PubMed ID: 16307862
[TBL] [Abstract][Full Text] [Related]
15. Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes.
Duhamel MC; Troncy E; Beaudry F
Biomed Chromatogr; 2010 Aug; 24(8):868-77. PubMed ID: 20020418
[TBL] [Abstract][Full Text] [Related]
16. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.
Riley RJ; McGinnity DF; Austin RP
Drug Metab Dispos; 2005 Sep; 33(9):1304-11. PubMed ID: 15932954
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
18. Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s.
Tang C; Chiba M; Nishime J; Hochman JH; Chen I; Williams TM; Lin JH
Drug Metab Dispos; 2000 Jun; 28(6):680-6. PubMed ID: 10820141
[TBL] [Abstract][Full Text] [Related]
19. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s.
McGinnity DF; Parker AJ; Soars M; Riley RJ
Drug Metab Dispos; 2000 Nov; 28(11):1327-34. PubMed ID: 11038161
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
